The role of ,&blockade therapy for ventricular tachycardia induced with isoproterenol: A prospective analysis lsoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role of Pblockade for treatment of such VT has not been critically assessed. The use of B-blockade was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 + 1.3 (? S. D.) pg/min to induce sustained monomorphic VT (>30 seconds, or requiring termination due to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry (group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with propranolol alone (0.2 mg/kg), verapamil alone (0.15 mg/kg), and propranolol plus verapamil, and group C had serial tests with propranolol alone, procainamide or quinidine (class la drug) alone, and propranolol plus a class la drug until VT could no longer be induced. All six patients in group A responded to propranolol alone. In group B, one patient responded to verapamil alone, and two patients responded to propranolol plus verapamll. In group C, three patients responded to propranolol alone, one patient responded to a class la drug alone, and one patient responded to propranolol plus a class la drug. During a follow-up of 7 to 37 (17.9 -t 10.7) (-tS. D.) months, VT has not recurred in any patient. Three patients treated initially with propranolol alone have required substitution of amiodarone due to refractory congestive heart failure. In patients requiring isoproterenol for VT induction, @blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry. (AM HEART J 1990; 120:1347.) Patients with recurrent, sustained monomorphic ventricular tachycardia (VT) sometimes require intravenous administration of ,&agonists such as isoproterenol for initiation of ventricular tachycardia in the cardiac electrophysiology laboratory.lv6 Traditionally, selection of appropriate antiarrhythmic therapy for the induced VT has been based upon the VT mechanism.5, 6 To date, a critical assessment of the role of P-blockade in the treatment of such dysrhythmias has not been undertaken. In this prospective study, the role of ,&blockade therapy was evaluated in consecutive patients who required isoproterenol for initiation of VT after a negative baseline cardiac electrophysiology study.
METHODS

Patient population.
Fourteen patients with recurrent, sustained monomorphic ventricular tachycardia were evaluated (Table I ). There were five males and nine females, with an age range of 14 to 78 years. Three patients had coronary artery disease with a history of myocardial infarction, four patients had valvular heart disease, three patients had right ventricular dysplasia, one patient had hypertensive heart disease, and three patients had no clinical evidence of structural heart disease. Three patients had VT associated with physical exertion, and one patient had VT occur during extreme emotional distress. Electrophysiology study protocol. Patients were studied in the postoperative, fasting state after discontinuation of antiarrhythmic therapy for at least 5 half-lives. Midazolam, 1 to 3 mg, was used intravenously for sedation. Three 6F quadripolar electrode catheters were inserted percutaneously into the right femoral vein and were positioned under fluoroscopic guidance against the high right atrium, the right ventricular apex, and across the tricuspid valve to record a His bundle potential. Surface electrocardiographic leads Vi, I, III, and intracardiac electrograms were recorded on a Siemens-Elema Mingograf recorder (Siemens Elema AB, Solna, Sweden) at paper speeds of 25 to 100 mm/set. A 12-lead electrocardiogram was also recorded whenever sustained monomorphic VT was initiated.
Stimulation was performed with a programmable stimulator (Bloom Associates, Ltd., Narberth, Pa.), with stimuli having a pulse width of 2 msec and a current twice diastolic threshold. Atria1 overdrive pacing was performed initially, beginning at a cycle length of 50 msec less than the spontaneous sinus cycle length and decreasing in 50 msec intervals to a minimum of 250 to 270 msec. Atria1 programmed stimulation with one and two atria1 extrastimuli was performed using an atria1 drive cycle length at least 200 msec greater than the atria1 cycle length that caused Wenkebach periodicity. Ventricular programmed stimulation was performed initially at the right ventricular apex. A similar protocol was performed at the right ventricular outflow tract if VT could not be initiated. Six to eight cycle drive trains were used with drive cycle lengths (SiSi) of 600 and 500 or 400 msec. The inter-train interval was 3 seconds. The coupling interval of the first extrastimulus (SiSz) was initially 520, 420, or 320 msec, respectively. SiSs was decreased in intervals of 10 msec until refractoriness to Sz occurred. SiSs was increased by 30 msec, and a second extrastimulus (S&J was initiated with an interval that was 300 msec greater than SiSs. SsSs was decreased in 10 msec intervals until refractoriness to Ss occurred, and was then increased by 20 to 30 msec. SiSs was then decreased again in 10 msec intervals until refractoriness of Sz occurred. After stimulation with Ss and Ss was completed with two drive cycle lengths, SiSs and SsSs were increased to 30 msec more than the effective refractory periods of Ss and Ss, respectively, and programmed stimulation was continued using a third extrastimulus (S&) that was 300 msec greater than SsSs. S& was decreased in 10 msec intervals until refractoriness to Sq occurred. S&Id was then increased by 20 to 30 msec, and SsS3 was decreased in 10 msec intervals until refractoriness to Se occurred. After SzSs was increased again by 30 msec, SiSz was decreased in 10 msec intervals until refractoriness to S2 occurred. After completion of programmed stimulation with E&S4 using two drive cycle lengths, ventricular burst pacing was performed using drive cycle lengths of 600 to 260 msec with drive trains of 15 cycles. The drive cycle length was decreased by 20 msec after each train was delivered. The inter-train interval was 3 seconds. Programmed stimulation at the right ventricular outflow tract was performed after completion of the protocol at the right ventricular apex.
Infusion of isoproterenol.
After completion of programmed stimulation, isoproterenol was infused at rates of 0.5 to 4.0 rg/min (mean f S. D. = 2.4 f 1.3 rg/min). The spontaneous sinus cycle length decreased by 32 + 13 % . If VT did not occur spontaneously during isoproterenol administration, programmed stimulation was repeated at both right ventricular sites, as previously described.
Definitions
of mechanisms of induced ventricular tachycardia. The following principles of clinical electrophysiology were utilized to classify the mechanisms of the induced VTs.'
Enhanced automaticity (group A). VT could not be induced by programmed stimulation but occurred spontaneously during isoproterenol infusion with varying coupling intervals between the last sinus rhythm QRS complex and the initial VT QRS complex. The initial VT QRS complex had the same morphology as the monomorphic VT. The VT could not be converted to sinus rhythm by overdrive pacing or programmed stimulation, and the VT morphology and cycle length did not change after overdrive pacing. Advancement of the first post-pacing VT QRS complex did not occur after overdrive pacing. The VT resolved only with discontinuation of isoproterenol.
Triggered automaticity (group B). VT could be initiated consistently over a specific range of cycle lengths during burst ventricular pacing without ventricular extrastimuli. The VT cycle length varied with the burst pacing cycle length. The first VT QRS complex occurred late in the cardiac cycle. This VT could be terminated by burst ventricular pacing.
Reentry (group C). VT was initiated with ventricular extrastimuli and could be terminated by overdrive pacing. Advancement of the first post-pacing VT QRS complex was sometimes observed when burst pacing or programmed extrastimuli failed to successfully terminate the induced VT.
Electropharmacologic testing
Groups A and B. During initial electropharmacologic testing, propranolol, 0.2 mg/kg, was administered intravenously and repeat testing was performed using the same dose of isoproterenol required to induce VT during the -1sec -I Fig.   2 . A through C. In this patient (No. 12) with triggered automaticity, sustained VT could be induced only by ventricular overdrive pacing during isoproterenol administration. VT was consistently induced by ventricular overdrive pacing at cycle lengths @iSi) of 340 and 360 msec (panels C and D), but not at cycle lengths greater than 380 msec (panels A and B) or less than 320 msec (panels E and F). This VT was not suppressed with intravenous propranolol alone or verapamil alone, but was suppressed with combined therapy with propranolol and verapamil. Ventricular electrograms from the right ventricular apex (RVA) are shown. Other abbreviations are the same as in Fig. 1 .
baseline study. If propranolol alone did not suppress reinduction of VT, electropharmacologic testing was reing upon heart rate and blood pressure response, and testing was repeated. peated after a minimum of 48 hours using an intravenous dose of verapamil alone (0.15 mg/kg). If verapamil alone did not suppress reinduction of VT, propranolol was administered in doses of 0.1 to 0.2 mg/kg, dependGroup C. Initial electropharmacologic testing of propranolo1 was performed in a manner similar to that for groups A and B. If propranolol alone did not suppress reinduction of VT, electropharmacologic testing was repeated after a minimum of 48 hours with intravenously administered procainamide or quinidine (10 mg/kg load and 0.06 to 0.075 mg/kg/min). If the class Ia drug did not suppress reinduction of VT, propranolol was readministered in a dose of 0.2 mg/kg and electropharmacologic testing was repeated. All patients underwent final testing of orally administered drugs before hospital discharge to confirm that VT was not inducible using the previously described protocol before and during isoproterenol administration.
Follow-up.
All patients were followed as outpatients with office visits every 2 to 3 months for the first 6 months, and with office visits or telephone contact every 3 months thereafter.
RESULTS
The results of electrophysiologic and electropharmacologic testing are summarized in morphic VT (duration > 30 seconds, or requiring intravenous isoproterenol administration, the spontermination due to hemodynamic collapse) was intaneous sinus cycle length decreased to 570 + 130 duced a minimum of three times in each patient durmsec 0, < 0.05, paired t test). During continued isoing isoproterenol administration. The spontaneous proterenol administration after intravenous adminsinus cycle length during the baseline study was istration of propranolol, the spontaneous sinus cycle 840 a 140 msec (mean k SD. Six patients had enhanced automaticity (group A) (Fig. l) , three patients had triggered automaticity (group B) (Fig. 2) , and five patients had reentry (group C) (Fig. 3) .
Electropharmacologic
testing. OVerdl, 9 of 14 patients (64%) had reinduction of VT suppressed by propranolol alone. Three of 14 (21%) patients required propranolol combined with other drug therapy to prevent VT reinduction.
The presence of both p1 and Pz-adrenoreceptors in the human heart has been demonstrated by radioligand studies.gp lo Both receptor subtypes appear to be involved in increasing tissue levels of cyclic adenosine monophosphate. "1 l2 Isoproterenol is a nonselective agonist, whereas propranolol is a nonselective antagonist of both 81 and 82 receptors.13r I4 The potential role that these receptors have in mediating activation of each VT mechanism is discussed separately. Group A. All six patients with enhanced automaticity had reinduction of VT suppressed by propranolo1 alone.
Group B. None of the three patients with triggered automaticity had VT reinduction suppressed by propranolol alone. One patient had reinduction of VT suppressed by verapamil alone. Two patients had reinduction of VT suppressed by propranolol plus verapamil. Group C. Three patients with reentry had reinduction of VT suppressed by propranolol alone. One patient had reinduction of VT suppressed by a class Ia drug alone, and one patient had reinduction of VT suppressed by propranolol plus a class Ia drug after failing to respond to a therapeutic serum concentration of the class Ia drug alone. Follow-up. Follow-up has ranged from 5 to 37 (mean -t S.D. = 17.9 + 10.7) months. VT has not recurred spontaneously in any patient. Three patients treated initially with propranolol alone developed refractory congestive heart failure despite preload and afterload therapy. Because of its indirect flblocking effects and negligible negative inotropic effects when administered orally, amiodarone was substituted.8 None of these three patients had inducible VT after 10 days of oral loading (800 mg twice a day), and no patient has had a spontaneous recurrence of VT during long-term oral amiodarone administration (200 mg daily).
Enhanced automaticity.
Spontaneous depolarizations occur most commonly in cells with slow-response action potentials. 15p l6 In isolated cardiac fiber models of spontaneous automaticity, the number of functioning slow channels appears to depend upon cyclic adenosine monophosphate (CAMP). During resting conditions, therefore, there may not be sufficient slow inward current to cause slow-response action potentials to occur.17 In this setting, it would be anticipated that ,&receptor stimulation with isoproterenol might cause automatic VT to occur. Conversely, propranolol would be expected to be effective in suppressing such an automatic dysrhythmia.
In the present study, all patients with VT due to enhanced automaticity had VT reinduction suppressed by P-blockade. Sung et all8 have previously reported the failure of verapamil to suppress VT due to catecholamine-sensitive automaticity, and have postulated that this dysrhythmia may not be caused by a slow channel mechanism that is calcium-dependent in humans.
DISCUSSION
Isoproterenol
is commonly used to facilitate the induction of clinically significant VT when it cannot be induced by standard ventricular programmed stimulation or burst ventricular pacing.le6 As observed in this and earlier studies, many of these patients' VTs are not necessarily exercise-induced.5y 6 The number of patients requiring isoproterenol to initiate VT make up a small proportion of the total number of patients whose VT is induced in the cardiac electrophysiology laboratory. Of the patients whose VT requires isoproterenol for initiation, a smaller proportion have coronary artery disease tions result in either reduction of both the action potential and the amplitude of delayed action potentials, or in prevention of delayed afterdepolarization altogether.20v 26 In the present study, however, the administered intravenous doses of propranolol alone and verapamil alone were insufficient for uniformly suppressing triggered automaticity activated by isoproterenol. In two of the three patients with triggered automaticity, the synergistic effects of P-adrenoreceptor blockade and calcium channel antagonism appeared to be necessary to suppress reinduction of VT.
Reentry. Reentry is a dynamic process that requires an area of unidirectional impulse block and recirculation of the impulse to its original point of block.2' When reentry cannot be initiated during resting conditions, the discrete responses of individual cardiac fibers to isoproterenol stimulation may create the milieu for reentry to occur. Under such conditions, differential shortening of the refractory period of individual fibers caused by isoproterenol provides a course for impulse propogation along fibers that have a shorter refractory period, and blocking in one direction in fibers having a longer refractory period.28l 2g
In the presence of isoproterenol, P-blockers in concentrations causing ,&blockade alone can reverse isoproterenol's accelerating effects on repolarization. 30 The inability to reinduce reentrant VT after propranolol administration in three of the five patients in the present study may have been due to this phenomenon. In addition to competitive inhibition of catecholamine binding at P-receptor sites, P-blockers have been demonstrated to exhibit direct membranestabilizing action, i.e., "quinidine-like" blockade of the inward sodium current. However, this latter action has been observed only at concentrations that are up to 100 times greater than the clinical concentrations causing P-blockade. [31] [32] [33] [34] Comparison with previous studies. Few studies have critically evaluated the role of P-blockade in suppressing VT that requires isoproterenol for its activation. Some studies have utilized intravenous doses of propranolol that may have been too small to effect adequate blockade of isoproterenol during electropharmacologic testing, or have not routinely tested propranolol in consecutive patients.5, 6 One study3" has reported upon the long-term effectiveness of empiric oral B-blocker therapy for patients requiring isoproterenol for facilitation of VT induction during extrastimulus testing. However, only two of the nine patients in that study had sustained VT induced prior to antiarrhythmic therapy.35 To our knowledge, ate the role of P-blockade in consecutive patients requiring isoproterenol for induction of sustained VT.
Conclusions.
In patients requiring isoproterenol for ventricular induction, p-blockade alone appears to be effective in preventing reinduction of VT caused by enhanced automaticity.
A heterogeneous response occurs when the VT mechanisms are triggered automaticity or reentry. The similarity of the sinus cycle lengths measured after treatment with intravenous propranolol treatment during continuous isoprotereno1 administration, when compared with the sinus cycle lengths measured during the baseline study, suggests that adequate blockade of isoproterenol's fl-agonistic effects should have been achieved with the dose of propranolol administered in this study. The failure of propranolol alone to uniformly suppress all VT activated during isoproterenol administration in this study could have several possible explanations. These include: (1) differences in the total number and the ratio of the subtypes of ,f3-adrenoreceptors that mediated activation of VT mechanisms in individual patientslO> 36; (2) differences in the affinity of these receptors for propranolol and/or isoproterenol when compared with normal human cardiac /3-receptors37; and (3) differences in the intrinsic activity of individual patient's &receptors in response to isoproterenol and/or propranolol."s Patients who did not respond to intravenously administered propranolol were not retested during long-term oral propranolol administration. Therefore it is possible that the failure of immediate and complete P-blockade to suppress VT reinduction may not have predicted the results of long-term therapy.3g Further investigation will be necessary to substantiate the findings of the present study and to better define the role of P-adrenoreceptor activation and blockade in human VT mechanisms. the present study is the first to prospectively evalu-5. Reddy CP, Gettes LS. Use of isoproterenol as an aid to elec-
